Targeting High-Risk Pediatric Solid Tumors With CAR T Cells Directed Against ALK (Anaplastic Lymphoma Kinase, CD246)

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-2-s3-p40